A mammal suffering from allergic disease due to SRS-A, such as skin symptoms, asthma, rhinitis, etc. is treated by administering to said mammal an effective amount of a compound of the formula: ##STR1## wherein R is methoxy or methyl, or two R's taken together represent --CH.dbd.CH--CH.dbd.CH--; and n is an integer of 4 to 22.
Compounds of the formula ##STR1## wherein A is methylene or carbonyl, n is an integer of 2 to 21, inclusive, and R is hydrogen or lower alkyl, are effective for the prophylaxis or treatment of mammals suffering from fibrosis due to excessive collagen accumulation.
A compound of the formula: ##STR1## [wherein either one of R.sub.1 and R.sub.2 stands for hydrogen or SO.sub.3 H and the other is SO.sub.3 H, Z stands for ##STR2## (where m denotes an integer of 1-22, n denotes an integer of 0-21, R.sub.3 stands for hydrogen or an acyl group having 2 to 4 carbon atoms, and R.sub.4 is hydrogen or an alkyl group having 1 to 4 carbon atoms)] and pharmacologically acceptable salts thereof, which has various pharmacological actions such as antioxidative action, inhibitory action of SRS-A generation, immunoregulatory action, action on lysosome-membrane, cell-activating action, phosphodiesterase-inhibitory action, etc.
Quinone derivatives of the general formula: ##STR1## (wherein R.sup.1 and R.sup.2 are the same or different, and independently are a hydrogen atom or a methyl or methoxy group, or R.sup.1 and R.sup.2 combine with each other to represent --CH.dbd.CH--CH.dbd.CH--; R.sup.3 is a hydrogen atom or a methyl group; R.sup.4 is an aliphatic, aromatic or heterocyclic group which may be substituted; R.sup.5 is a methyl or methoxy group, a hydroxymethyl group which may be substituted or a carboxyl group which may be esterified or amidated; Z is a group represented by --C.tbd.C--, --CH.dbd.CH--, ##STR2## n is an integer of 0 to 10; m is an integer of 0 to 3; k is an integer of 0 to 5, provided, however, that in the case of m being 2 or 3, Z and k can vary arbitrarily within the bracketed repeating units) are novel compounds, possess metabolism ameliorating action for polyunsaturate fatty acids, particularly production inhibitory activity of lipid peroxides (antioxidant activity), thromboxane A.sub.2 receptor antagonism, or production inhibitory activity of 5-lipoxygenase metabolites in mammals, and of use as drugs, such as antiasthmatic, antiallergic agent and cerebral-circulatory metabolism ameliorating agent.
Quinone derivatives of the general formula: ##STR1## (wherein R.sup.1 and R.sup.2 are the same or different, and independently are a hydrogen atom or a methyl or methoxy group, or R.sup.1 and R.sup.2 combine with each other to represent --CH.dbd.CH--CH.dbd.CH--R.sup.3 is a hydrogen atom or a methyl group; R.sup.4 is an aliphatic, aromatic or heterocyclic group which may be substituted; R.sup.5 is a methyl or methoxy group, a hydroxymethyl group which may be substituted or a carboxyl group which may be esterified or amidated; Z is a group represented by --C.dbd.C--, --CH.dbd.CH--, ##STR2## n is an integer of 0 to 10; m is an integer of 0 to 3; k is an integer of 0 to 5, provided, however, that in the case of m being 2 or 3, Z and k can vary arbitrarily within the bracketed repeating units) are novel compounds, possess metabolism ameliorating action for polyunsaturated fatty acids, particularly production inhibitory activity of lipid peroxides (antioxidant activity), thromboxane A.sub.2 receptor antagonism, or production inhibitory activity of 5-lipoxygenase metabolites in mammals, and of use as drugs, such as antiasthmatic, antiallergic agent and cerebral-circulatory metabolism ameliorating agent.
The present invention provides a novel methoda for preventing deep vein thrombosis comprising the administration of lipoxygenase inhibitors of Formula I ##STR1##
